The Global Discovery Chemistry (GDC) Platform is at the center of drug discovery research at NIBR, focusing on the design and synthesis of potential drug molecules. Spanning several disciplines from computational and experimental chemistry to automation and robotics, researchers work in teams to study these new molecules and select those that have the greatest potential to help patients.
Disease Area Chemistry
The Disease Area chemistry units work in close collaboration with the disease experts on early-stage discovery projects from the synthesis and testing, to the ultimate selection of a drug candidate.
Early Discovery Chemistry
The two Early Discovery Chemistry units (EDC) in Basel, Switzerland and Cambridge, US are involved in modifying and optimizing the properties of promising compounds for improved binding to the target and reducing potential toxicity. They work in close collaboration with all disease experts as well as with the Molecular and Developmental Pathways Group and the Epigenetics Platform.
Early Medicinal Chemistry
The Early Medicinal Chemistry (EMC) unit involves synthesizing compounds that have a large diversity of properties, or specific properties for a targeted application. This group is concerned with the identification of attractive chemical starting points for difficult targets; peptides and Antibody Drug Conjugates (ADCs).
Computer-Aided Drug Design
The Computer-Aided Drug Design (CADD) group replicates chemical interactions and properties onto computers. Their task is to find ways to predict how chemical compounds and disease targets might behave and interact, in order to make the search for new drugs more efficient. These predictions are determined by using structure-based models, combinatorial library designs driven by specific sets of properties, cheminformatics software calculations, and database comparisons of ADME/toxicology in novel compounds.
Preparations, Separations and Bioreactions
The Preparations, Separations and Bioreactions (PSB) group provides expertise and services in three domains: preparative-scale chemical synthesis, separation technologies of biologically active compounds, and biochemical transformations.
Understanding the underlying molecular basis of disease has enabled NIBR to turn scientific insights into medical breakthroughs.
Drug discovery and development process